Search research articles
Contact Us
Filters
Showing results (81-90 of 131) with videos related to
Page
of 14
Sort By:
The Lancet. Haematology
|
April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
British Journal of Haematology
|
November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2024
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
Ilaria Colombo, Kira-Lee Koster, Lisa Holer, et al.
ESMO Open
|
October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Blood Advances
|
September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi, Eugenio Gaudio, Paola Bonetti, et al.
Cancer Chemotherapy and Pharmacology
|
June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
Anna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Haematologica
|
August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
Paolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas
Anastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 131) with videos related to
Sort By:
Page
of 14
The Lancet. Haematology
|
April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
British Journal of Haematology
|
November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2024
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
Ilaria Colombo, Kira-Lee Koster, Lisa Holer, et al.
ESMO Open
|
October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Blood Advances
|
September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi, Eugenio Gaudio, Paola Bonetti, et al.
Cancer Chemotherapy and Pharmacology
|
June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
Anna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Haematologica
|
August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
Paolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas
Anastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Page
of 14